Highlights Newsletter 2 This newsletter presents you the following key sessions: Watch the video interview with Professor Jonathan Ledermann, MD, PhD, about the results of the phase III SOLO1 trial: maintenance with olaparib following chemotherapy results in a significant benefit in progression-free survival in patients with BRCA1/2 mutated advanced ovarian cancer Final overall survival data from PALOMA-3 assessing palbociclib plus fulvestrant in women with HR+/HER2- advanced breast cancer failing previous hormonal therapy Local radiotherapy improves survival in metastatic prostate cancer patients with low disease burden Longer survival and delayed disease progression when adding S-1 to gemcitabine-cisplatin in newly diagnosed patients with advanced biliary tract cancer Chemoradiotherapy should remain the standard of care for patients with HPV-positive oropharynx cancer